A global leader in medical technology, Medtronic, has been granted CE (Conformité Européenne) Mark for the Hugo™ robotic surgery (RAS) system, giving the green light for sales of the system in Europe. The approval has been given for urologic and gynecologic procedures which when combined, make up approximately 50% of all robotic procedures performed today. Hugo RAS system will help to mitigate cost and utilization barriers that have suffocated the implementation of robotic surgery adoption for the past 20 years. While robotic surgery give patients the option of minimally invasive surgery which include fewer complications, shorter hospital stays, and in general, a faster recovery, only 3% of surgeries are performed robotically and 2% of procedures are done robotically in Western Europe. In the US, the Hugo RAS system is an investigational device and is yet to be commercially approved.

Read more here.

More on: